BOSTON and ROLLE, Switzerland, Nov. 5, 2024
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native
software company and leader in data-driven medicine, today
announced that Ross Muken,
previously Chief Financial Officer ("CFO") and Chief Operating
Officer ("COO"), has been promoted to company President, effective
November 5, 2024. George Cardoza has been appointed as the
company's new CFO.
In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global
business operations and work even more closely on strategic
planning with CEO, Jurgi Camblong. He will continue to lead the
company's go-to-market function, including Clinical sales,
BioPharma Dx sales, sales support, marketing, customer experience,
and operations. Ross joined SOPHiA GENETICS in February 2021 as CFO and was appointed as CFO and
COO in March 2023.
"I want to congratulate Ross on his well-deserved promotion to
President," said Jurgi Camblong, SOPHiA GENETICS CEO and
Co-Founder. "Ross has been an instrumental part of our success
since he joined almost four years ago, first as CFO and more
recently as COO. I am grateful for his trusted partnership in
positioning SOPHiA GENETICS for long-term growth."
Jurgi Camblong adds, "I am also delighted to welcome
George Cardoza to our executive
leadership team. George is a proven business leader and brings a
wealth of deep financial expertise, leadership experience, and
industry knowledge to SOPHiA GENETICS. As we continue to grow,
George is uniquely qualified to help us succeed in this next
exciting chapter of our journey. The leadership of both Ross and
George will be crucial as we continue to further enhance our
operational effectiveness while also balancing our need to
consistently innovate."
As CFO, Cardoza will oversee all corporate finance functions,
including accounting, financial planning and analysis ("FP&A"),
investor relations, internal audit, tax, and treasury.
Mr. Cardoza brings more than 30 years of experience in the
precision medicine and clinical diagnostics industry, with
extensive experience in both financial and operational leadership.
Before joining SOPHiA GENETICS, he was the CFO and Head of Service
Delivery at Biocartis, a molecular diagnostics company. Prior, he
spent over twelve years with NeoGenomics Laboratories in
several executive roles (CFO, President Pharma Services Division,
and President and Chief Operating Officer Laboratory Operations),
and previously spent more than fourteen years with Quest
Diagnostics in various roles including Controller of the Central
Region.
Throughout his career, Cardoza has shown a strong talent for
financial management, strategic planning, and driving businesses
towards increasing levels of performance. He has a deep
understanding of the industry landscape and a proven track record
of success in executing and influencing growth-oriented business
strategies. Mr. Cardoza holds a B.S. in Finance and Accounting from
Syracuse University and an MBA from
Michigan State University.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare
technology company on a mission to expand access to data-driven
medicine by using AI to deliver world-class care to patients with
cancer and rare disorders across the globe. It is the creator of
SOPHiA DDM™, a platform that analyzes complex genomic and
multimodal data and generates real-time, actionable insights for a
broad global network of hospital, laboratory, and biopharma
institutions. For more information, visit SOPHiAGENETICS.COM and
connect with us on LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-promotes-ross-muken-to-president-and-appoints-george-cardoza-as-chief-financial-officer-302295836.html
SOURCE SOPHiA GENETICS
